| scholarly article | Q13442814 |
| P2093 | author name string | Jun Ye | |
| Hong Yu | |||
| Li Zhu | |||
| Lin Jiang | |||
| Xiaoli Ji | |||
| Haihui Sheng | |||
| Yumin Xu | |||
| Jingjing Bao | |||
| Yabin Zhu | |||
| Qinxiao Jiang | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study | Q24293230 | ||
| Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Q26782024 | ||
| A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane | Q28143113 | ||
| Newly identified loci that influence lipid concentrations and risk of coronary artery disease | Q28264535 | ||
| Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins | Q28276232 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study | Q33621145 | ||
| The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. | Q34276618 | ||
| The discovery and development of HMG-CoA reductase inhibitors. 1992. | Q34552470 | ||
| Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease | Q35062523 | ||
| HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials | Q35065253 | ||
| Annual report on status of cancer in China, 2011 | Q35085507 | ||
| Methylenetetrahydrofolate reductase C667T polymorphism is associated with increased risk of coronary artery disease in a Chinese population | Q35225223 | ||
| The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis. | Q35513253 | ||
| Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy | Q36758129 | ||
| Problems and possible solutions for therapy with statins | Q37007848 | ||
| The genetic determinants of atorvastatin response. | Q37015861 | ||
| High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy | Q37254454 | ||
| Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi | Q37312136 | ||
| Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects | Q37474395 | ||
| Transporter pharmacogenetics and statin toxicity | Q37627544 | ||
| Drug transporters in drug efficacy and toxicity | Q37937670 | ||
| Combination therapy in dyslipidemia: where are we now? | Q38258490 | ||
| Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. | Q38336252 | ||
| Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia | Q39103398 | ||
| Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy | Q39846276 | ||
| Statin Function as an Anti-inflammation Therapy for Depression in Patients With Coronary Artery Disease by Downregulating Interleukin-1β. | Q40510911 | ||
| SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients | Q42199862 | ||
| Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia | Q42654954 | ||
| ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin | Q43174441 | ||
| Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia | Q43416438 | ||
| Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. | Q45970166 | ||
| Association between the ABCG2 C421A polymorphism and Alzheimer's disease | Q46045432 | ||
| Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients | Q46062183 | ||
| Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate | Q46365149 | ||
| Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and susceptibility to ischemic stroke: a meta-analysis. | Q53128366 | ||
| Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. | Q53568394 | ||
| Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? | Q53611791 | ||
| Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. | Q54274187 | ||
| Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response | Q57083795 | ||
| LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease | Q57316348 | ||
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
| Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort | Q61895079 | ||
| CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin | Q84772643 | ||
| [Lipid control in high-risk patients: focus on PCSK9 inhibitors] | Q86756157 | ||
| P433 | issue | 8 | |
| P921 | main subject | coronary artery disease | Q844935 |
| P304 | page(s) | 8795-8803 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | International Journal of Clinical and Experimental Pathology | Q6051341 |
| P1476 | title | Utility of genetic variants to predict prognosis in coronary artery disease patients receiving statin treatment | |
| P478 | volume | 10 |
Search more.